Business Strategy

The BioAlliance business strategy is based on combining the specialty pharmaceutical model with the biotech model of New Entities drug development, targeting specific hospital markets.

By focusing the drug delivery systems on reformulation and delivery of approved pharmaceutical agents having known safety and efficacy, the company is able to capitalize on this existing data, reducing overall development risk while shortening the time and cost of developing products.

For example, our first products in the Lauriad® platform include delivery of the widely used generic drugs, miconazole and acyclovir. In our Transdrug® nanotechnology program our first product includes doxorubicin, a widely used, generic chemotherapeutic agent known as a potent anti-cancer compound registered in numerous cancers, and characterized by an innovative pharmacological profile designed to overcome drug resistance.

In this way, by focusing on the reformulation and improved delivery of known drugs, the drug delivery programs provide the company with a firm revenue generating foundation upon which to explore the higher risk product opportunities represented in the New Entities program, the kind of activity associated more typically with the pure biotech business model. In the near term, it is the more advanced Lauriad® adhesive technology Phase III program that will support this strategy, followed by the Transdrug® nanoparticle program, should it prove successful.

In sum, the company’s novel drug delivery technologies will serve to insulate BioAlliance from the downside risk of a single focus on development of New Entities while providing the investor with near term value creation, a growing revenue stream and the considerable upside potential represented by New Entities development in oncology and HIV.